摩根士丹利发表报告,对上海医药目标价由17港元上调至18港元,相当于预测2026年市盈率9.7倍,评级“增持”。该行将上海医药2025至2030年的盈利预测上调1至11%,原因是分销和制造业务的销售额增加。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.